Australia markets closed

TEVA Mar 2025 12.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.4800+0.1300 (+37.14%)
At close: 10:00AM EDT
Full screen
Previous close0.3500
Open0.4800
Bid0.3000
Ask0.4400
Strike12.00
Expiry date2025-03-21
Day's range0.4800 - 0.4800
Contract rangeN/A
Volume2
Open interest539
  • Reuters

    Teva sues Corcept over mifepristone 'monopoly' for rare disorder

    Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.

  • Business Wire

    Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.

  • Zacks

    TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

    TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.